Biogen Inc.'s Stock Analysis

Biogen Reports $34 Million Expense Impacting Q1 Earnings

Biogen anticipates a pre-tax expense of approximately $34 million related to acquired in-process research and development, upfront, and milestone costs for the first quarter of 2026. This charge is expected to affect both GAAP and non-GAAP net income per diluted share by about $0.19. The expenses are associated with collaboration and licensing agreements, including upfront payments and milestone payments.

The results for the quarter ending March 31, 2026, are still preliminary and subject to finalization. There is no assurance that the final results will align with the current estimates. Investors are advised that actual results may differ significantly due to various risks and uncertainties, and they should refer to Biogen's Annual Report and other filings for more information on potential risks.

Apr 06, 2026 06:31:37

Biogen Enters Agreement to Acquire Apellis Pharmaceuticals

Biogen Inc. has entered into a definitive Merger Agreement with Apellis Pharmaceuticals, where Biogen's wholly-owned subsidiary will commence a tender offer to acquire all outstanding shares of Apellis Common Stock at $41.00 per share in cash, along with a contingent value right that could yield additional payments based on future milestones. The offer will last for 20 business days and does not require a stockholder vote to proceed, with the merger expected to close after certain conditions are met, including antitrust approvals and the tender of shares representing more than 50% of Apellis' outstanding stock.

In conjunction with the merger, certain Apellis directors and shareholders, holding approximately 14% of the company's shares, have agreed to tender their shares in support of the transaction. The agreement includes provisions for a termination fee if the merger is not completed by September 30, 2026, and outlines restrictions on Apellis' ability to solicit alternative acquisition proposals. The transaction aims to enhance Biogen's portfolio, and both companies have committed to necessary regulatory filings to facilitate the merger process.

Mar 31, 2026 17:03:19

Biogen Chief Legal Officer to Depart by May 2026

Biogen Inc. announced that Susan H. Alexander, the Chief Legal Officer, will leave the company at the end of May 2026. The company has started the process of searching for her successor.

This leadership change may have implications for the company's legal strategies and overall governance. Investors will be watching the transition closely as the new appointment could influence the company's operations and regulatory compliance.

Mar 11, 2026 17:28:01

Biogen Chair Caroline Dorsa to Retire from Board in 2026

Caroline Dorsa, Chair of Biogen's Board of Directors, has announced that she will not seek re-election at the 2026 Annual Meeting of Stockholders. Her decision is not due to any disagreements regarding the company's operations or policies.

Following Dorsa's announcement, the Board has elected Dr. Maria C. Friere to take over as Chair effective after the Annual Meeting. This leadership transition may impact the company's governance structure moving forward.

Feb 11, 2026 17:07:38

Biogen Reports Q4 2025 Financial Results and 2026 Guidance

Biogen announced its financial results for the fourth quarter and full year 2025, reporting total revenue of $2.3 billion for Q4 and $9.9 billion for the full year. The company recorded a GAAP diluted EPS of $(0.33) for Q4 and $8.79 for the full year, with Non-GAAP diluted EPS of $1.99 for Q4 and $15.28 for the full year, surpassing previous guidance. Growth products contributed significantly, with LEQEMBI sales increasing 54% year-over-year. However, revenue from multiple sclerosis products, excluding VUMERITY, experienced declines, impacting overall revenue performance.

For 2026, Biogen provided financial guidance expecting Non-GAAP diluted EPS to range between $15.25 and $16.25, while total revenue is anticipated to decline by a mid-single-digit percentage compared to 2025. The company highlighted ongoing progress in its late-stage pipeline, including FDA Priority Review for LEQEMBI IQLIK and Breakthrough Therapy Designation for litifilimab. As of year-end 2025, Biogen had approximately $4.2 billion in cash and cash equivalents and $6.3 billion in total debt.

Feb 06, 2026 06:55:01

Biogen Reports $222 Million Expense Impacting Q4 2025 Earnings

Biogen Inc. anticipates a pre-tax expense of approximately $222 million related to acquired in-process research and development, upfront, and milestone expenses for the fourth quarter of 2025. This charge is expected to reduce both GAAP and non-GAAP net income per diluted share by about $1.26 for the quarter.

The company began presenting these expenses as a separate line item in its financial statements starting in the first quarter of 2025. The results for the fourth quarter of 2025 are still subject to finalization and may differ from the current preliminary estimates. Investors are advised to consider the uncertainties surrounding these expenses and their potential impact on the company's financial performance.

Jan 13, 2026 17:38:54

Biogen Reports Third Quarter 2025 Financial Results and Guidance

Biogen reported total revenue of $2.5 billion for the third quarter of 2025, marking a 3% increase from the previous year. The company achieved a GAAP diluted earnings per share (EPS) of $3.17, up 19% year-over-year, and a non-GAAP diluted EPS of $4.81, an 18% increase. Growth was driven by a 67% rise in revenue from launch products in Alzheimer's disease, rare diseases, and postpartum depression, with notable sales from LEQEMBI and SKYCLARYS. The company also highlighted progress in its late-stage pipeline programs and provided updates on key clinical trials and product launches.

Biogen updated its financial guidance for the full year 2025, now expecting non-GAAP diluted EPS to be between $14.50 and $15.00, reflecting a stronger underlying business outlook. Total revenue is projected to be approximately flat to increasing by 1% compared to 2024. The company anticipates increased competitive pressures in the ex-U.S. multiple sclerosis market, particularly for TECFIDERA, and plans to invest in research and development to support pipeline expansion. Additionally, Biogen announced recent licensing and acquisition agreements aimed at enhancing its product offerings.

Oct 30, 2025 06:13:59

Biogen Reports $2 Million Expense Impacting Q3 Earnings Per Share

Biogen Inc. anticipates a pre-tax expense of approximately $2 million related to acquired in-process research and development for the third quarter of 2025. This expense is expected to affect both GAAP and non-GAAP net income per diluted share by about $0.01. The company has begun presenting this expense as a separate line item in its financial statements, which includes costs from collaboration and license agreements.

The financial results for the quarter ending September 30, 2025, are still being finalized and may differ from these preliminary estimates. Biogen has noted that it cannot predict future occurrences of such expenses due to their uncertain nature, and investors are advised to consider the potential risks involved as outlined in the company's previous reports.

Oct 14, 2025 16:19:10

Biogen Reports Q2 2025 Financial Results and Guidance Update

Biogen reported total revenue of $2.6 billion for Q2 2025, reflecting a 7% increase year-over-year. The company reported a GAAP diluted EPS of $4.33, an 8% increase, and a Non-GAAP diluted EPS of $5.47, up 4% year-over-year. Key growth drivers included strong sales from Alzheimer's disease treatments, particularly LEQEMBI, which saw U.S. sales of approximately $63 million and global sales of around $160 million. Other notable revenue contributions came from SKYCLARYS and ZURZUVAE, with respective revenues of $130 million and $46 million, indicating significant growth in demand for these products. Biogen also announced advancements in its late-stage pipeline, including the initiation of Phase 3 studies for several treatments in rare diseases.

The company has raised its full-year 2025 guidance, now expecting Non-GAAP diluted EPS between $15.50 and $16.00, up from a previous range of $14.50 to $15.50. Total revenue is expected to remain flat year-over-year at constant currency, an improvement from prior expectations of a mid-single-digit decline. The guidance reflects strong performance in the first half of 2025, although Biogen anticipates increased competitive pressures in the second half, particularly for its multiple sclerosis products in Europe. The company plans to invest in R&D to support its clinical development activities, particularly in rare diseases, while also aiming for significant cost savings through its

Jul 31, 2025 06:13:54

Biogen Reports Estimated Q2 2025 Expenses Impacting Earnings

Biogen Inc. anticipates that its GAAP and non-GAAP results for the second quarter of 2025 will reflect approximately $46 million in acquired in-process research and development expenses. This expense is expected to reduce net income per diluted share by about $0.26. The company has started reporting these expenses as a separate line item in its financial statements, which include costs related to collaboration and license agreements.

The financial results for the quarter ending June 30, 2025, are still being finalized and may differ from the preliminary estimates provided. Biogen has noted that it does not forecast these expenses due to the inherent uncertainties surrounding their occurrence and timing. Investors are advised that the final results will be subject to closing procedures and could vary from the current estimates.

Jul 07, 2025 16:10:34